I have a PhD in political science and have been investing for well over a decade. I generally follow small cap biotechnology, MLPs, and mining companies. I hope to provide my thoughts on both topics of interest to investors and particular companies. See all of my reports at www.sobekanalytics.com Follow me on twitter: @dsobek.
I consider myself a 50/50 technical/fundamental trader and investor. I have carved a niche in analyzing small cap biotechnology companies and analyzing trial data, design and company structure. I mainly trade catalyst-driven stocks with good cash positions and promising therapies. Overall, my specialty is trial data. Over the past 6 years of research and investing, I have learned of the many ways to make money trading these extremely volatile and speculative biotech plays, particularly by making the best assumptions and educated guesses possible on trial data and company structure and management. I play the FDA calendar and pick the best companies possible for run-ups to data. I also do research for Stockmatusow.com, and collaborate with Scott Matusow and Kyle Dennis on articles and trade calls.
I am a personal investor and an attorney. I have extensive experience in the consumer credit arena as well as commercial real estate as an investor and a lender. I co-manage a commercial, hard money mortgage fund and also have experience with the Food, Drug & Cosmetic Act.
I have a B.S. in biochemistry along with a doctorate of pharmacy. The majority of my career has been spent in pain management, retail and primary care settings. I do have experience in transplant and acute care facilities although these aren't my strengths. I consider my strengths metabolic syndrome related diseases and pain management. Although I am new to analyzing the financials of a company, I have vast experience in primary literature analysis and my career gives me unique insight to what medications will be prescribed/profitable. I am not a writer and if I do post comments or write an article I apologize in advance for poor grammar, spelling and flow.
Trader of equities and options for over 12 years. Proprietary trading strategy involving options and biotech with a very high win to loss ratio. SMID cap biotech. Passionate about science and cooking.
"Win or lose, everybody gets what they want out of the market. Some people seem to like to lose, so they win by losing money."
Active investor/trader with a particular interest in "under the radar" companies in the biotech and alternative energy sectors. The purpose of my articles is to help educate and introduce investors to sound investment opportunities.
Hereby I declare that the views expressed in my posts are those of Alp Bugra Basat and do not necessarily reflect the views of my industry partners, research supervisors-collaborators and companies I have invested in.
I like basic science; if it is translated into new treatments. I like the biotechs with cutting-edge science. I don't like PI3K, ras, akt inhibitors. I like antibody-drug conjugates. I like sirtuin. I may not believe in β-amyloid. I really like ivacaftor. I am crazy about talimogene laherparepvec. I love the drugs like eteplirsen.
In addition, I don't fall in love with stocks, it means that my opinions expressed here can change in a milisecond, after I get more info.
A special thank goes to Osman Murat Bastopcu!
I'm an oncology PhD student at the University of California San Francisco (UCSF) in the Biomedical Sciences Program. I also enjoy long term, fundamental, biotech investing. My favorite investments MDVN, FPRX, and XNCR.